CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24B-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.
Term Extension and Supplementary Protection Certificate. Subject to Sections 5.2.3 and
5.2.6, Lilly shall have the right to make decisions regarding, and to apply for, patent term extensions in the Territory, including
the United States with respect to extensions pursuant to 35 U.S.C. §156 et. seq. and in other jurisdictions pursuant to supplementary
protection certificates, and in all jurisdictions with respect to any other extensions that are now or become available in the
future, wherever applicable, for the Lilly Patents, ACI Patents and any Joint Patents and with respect to the Licensed Compounds
and the Licensed Products, in each case including whether or not to do so; provided, that in the event ACI disagrees with
any such decision of Lilly, ACI shall have the right to escalate such dispute to the JSC for resolution in accordance with Section
5.2.3; provided further, that if the JSC resolves such dispute in favor of Lilly, then Lilly may proceed accordingly.
ACI shall provide prompt and reasonable assistance, as requested by Lilly, including by taking such action as patent holder as
is required under any Applicable Law to obtain such extension or supplementary protection certificate.
Ownership Under Joint Development Research Agreements. Notwithstanding anything to the
contrary in this Article 8, neither Party shall have the right to make an election under 35 U.S.C. 102(c) when exercising
its rights under this Article 8 without the prior written consent of the other Party. With respect to any such permitted
election, the Parties shall coordinate their activities with respect to any submissions, filings or other activities in support
thereof. The Parties acknowledge and agree that this Agreement is a “joint research agreement” as defined in 35 U.S.C.
Listings. The Parties shall, through the Patent Subcommittee, cooperate in good faith
and mutually agree upon all filings with Regulatory Authorities in the Territory with respect to the Lilly Patents, ACI Patents
and Joint Patents, including as required or allowed (i) in the United States, in the FDA’s Orange Book and (ii) in
the European Union, under the national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or other international
equivalents. As between the Parties, Lilly shall have the sole right to make all filings with Regulatory Authorities in the Territory
with respect to the Lilly Patents, including as required or allowed (a) in the United States, in the FDA’s Orange Book and
(b) in the European Union, under the national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or other international
Each Party shall promptly notify the other Party in writing of (i) any alleged or threatened
infringement of the ACI Patents, Lilly Patents or Joint Patents in the Field in any jurisdiction in the Territory or (ii) any
certification filed under the Hatch-Waxman Act claiming that any ACI Patents, Lilly Patents or Joint Patents are invalid or unenforceable
or claiming that any ACI Patents, Lilly Patents or Joint Patents would not be infringed by the making, use, offer for sale, sale
or import of a product for which an application under the Hatch-Waxman Act is filed or any equivalent or similar certification
or notice in any other jurisdiction in the Territory, in each case ((i) and (ii)) of which such Party becomes aware (an “Infringement”).